Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genaissance Pharmaceuticals (GNSC) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (17)	3/26/2001 9:10:09 PM
From: jeanmarcel	Respond to of 183

Hello Jim, You are right that was an interesting article. Hopefully with these discoveries in biotechnology the biotechnology sector will explode(especially GNSC). Thanks for the info, Jean-Marcel Staley

To: Jim Oravetz who wrote (17)	3/27/2001 9:39:17 AM
From: Bob Trocchi	Respond to of 183

Jim... I appreciated the link. Now I wish that I understood more of it. One certainly gets the impression that there is a lot going on in this area with a lot of small companies focusing on certain niches. In yesterday's Boston Globe (I will try and find the article later today and post it) it also covered a number of small companies all doing the same broad thing but each in their own niche. Feel like the computer and computer chip business some time ago and the networking business today. Cheers Bob T.

To: Jim Oravetz who wrote (17)	4/24/2001 8:04:25 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 183

Old News: San Francisco and New Haven - Sept. 21, 2000 - Telik, Inc. (Nasdaq: TELK) and Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) announced today that they have successfully completed a collaboration that involved the identification of compounds that exhibit activity against several novel gene variants, or haplotypes, of the estrogen receptor. Telik has acquired an exclusive right to license this joint intellectual property for further development and intends to seek partnerships with companies that have significant expertise in women's health. Both Telik and Genaissance will share in revenues derived from any licenses. "Genaissance successfully applied its advanced HAP(tm) Technology to discover certain estrogen receptor gene variants that may influence the efficacy and side effect profiles of drugs for estrogen-related diseases such as breast cancer and osteoporosis," said Michael M. Wick, M.D., Ph.D., Telik's chairman and chief executive officer. "By applying our TRAP drug discovery technology, we were able to identify several small molecules that have shown high affinity for certain variants that could enable the development of new drugs that can either target or avoid specific receptor variants for safer and more effective therapy." "Telik's TRAP chemogenomic drug discovery technology is well-suited to lead identification in the post-genomic era of drug discovery," said Gualberto Ruaño, Ph.D., M.D., chief executive officer of Genaissance. "Its speed and efficiency in lead identification are key attributes that contributed to the success of our collaboration." Telik, Inc. of South San Francisco, California, is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. The company's most advanced development programs are for the treatment of cancer and diabetes. Telik's product candidates were all discovered using its proprietary technology known as TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information can be found at www.telik.com. Genaissance Pharmaceuticals, Inc. is a leader in applying population genomics and informatics technologies to the development of personalized medicines. Genaissance discovers genomic markers that are predictive of drug response based on each patient's DNA. The Company markets its technology to the biopharmaceutical industry as a complete solution for improving drug development, marketing and prescribing. Genaissance is located in Science Park in New Haven, Connecticut. Additional information can be found at www.genaissance.com.